drugset / Trial / NCT07282353
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
RandomizedParallel-groupDouble-blindTreatment
Summary
A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA).
Timeline
- Start
- 2025-12-01
- Primary completion
- 2027-12-09
- Completion
- 2028-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS0159 | Unknown | 4 mg | Oral |